517 related articles for article (PubMed ID: 21936586)
1. Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data.
Samtani MN; Gopal S; Gassmann-Mayer C; Alphs L; Palumbo JM
CNS Drugs; 2011 Oct; 25(10):829-45. PubMed ID: 21936586
[TBL] [Abstract][Full Text] [Related]
2. Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia.
Gopal S; Gassmann-Mayer C; Palumbo J; Samtani MN; Shiwach R; Alphs L
Curr Med Res Opin; 2010 Feb; 26(2):377-87. PubMed ID: 20001492
[TBL] [Abstract][Full Text] [Related]
3. Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia.
Gopal S; Vermeulen A; Nandy P; Ravenstijn P; Nuamah I; Buron Vidal JA; Berwaerts J; Savitz A; Hough D; Samtani MN
Curr Med Res Opin; 2015 Nov; 31(11):2043-54. PubMed ID: 26306819
[TBL] [Abstract][Full Text] [Related]
4. Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial.
Bossie CA; Sliwa JK; Ma YW; Fu DJ; Alphs L
BMC Psychiatry; 2011 May; 11():79. PubMed ID: 21569242
[TBL] [Abstract][Full Text] [Related]
5. Extended-release intramuscular paliperidone palmitate: a review of its use in the treatment of schizophrenia.
Carter NJ
Drugs; 2012 May; 72(8):1137-60. PubMed ID: 22571444
[TBL] [Abstract][Full Text] [Related]
6. Paliperidone palmitate injection: Its efficacy, safety and tolerability in schizophrenia.
Owen RT
Drugs Today (Barc); 2010 Jul; 46(7):463-71. PubMed ID: 20683501
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychotic.
Samtani MN; Vermeulen A; Stuyckens K
Clin Pharmacokinet; 2009; 48(9):585-600. PubMed ID: 19725593
[TBL] [Abstract][Full Text] [Related]
8. Dosing and Switching Strategies for Paliperidone Palmitate 3-Month Formulation in Patients with Schizophrenia Based on Population Pharmacokinetic Modeling and Simulation, and Clinical Trial Data.
Magnusson MO; Samtani MN; Plan EL; Jonsson EN; Rossenu S; Vermeulen A; Russu A
CNS Drugs; 2017 Apr; 31(4):273-288. PubMed ID: 28258365
[TBL] [Abstract][Full Text] [Related]
9. A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia.
Coppola D; Liu Y; Gopal S; Remmerie B; Samtani MN; Hough DW; Nuamah I; Sulaiman A; Pandina G
BMC Psychiatry; 2012 Mar; 12():26. PubMed ID: 22455454
[TBL] [Abstract][Full Text] [Related]
10. A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia.
Fleischhacker WW; Gopal S; Lane R; Gassmann-Mayer C; Lim P; Hough D; Remmerie B; Eerdekens M
Int J Neuropsychopharmacol; 2012 Feb; 15(1):107-18. PubMed ID: 21777507
[TBL] [Abstract][Full Text] [Related]
11. A single-dose, open-label, parallel, randomized, dose-proportionality study of paliperidone after intramuscular injections of paliperidone palmitate in the deltoid or gluteal muscle in patients with schizophrenia.
Cleton A; Rossenu S; Crauwels H; Berwaerts J; Hough D; Gopal S; Eerdekens M; Vandebosch A; Remmerie B; De Meulder M; Rosso CM
J Clin Pharmacol; 2014 Sep; 54(9):1048-57. PubMed ID: 24676998
[TBL] [Abstract][Full Text] [Related]
12. Need for Bioequivalence Standards that Reflect the Clinical Importance of the Complex Pharmacokinetics of Paliperidone Palmitate Long-Acting Injectable Suspension.
Procyshyn RM; Lamoure JW; Katzman MA; Skinner PL; Sherman SE
J Pharm Pharm Sci; 2019; 22(1):548-566. PubMed ID: 31730504
[TBL] [Abstract][Full Text] [Related]
13. Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens.
Fu DJ; Bossie CA; Kern Sliwa J; Ma YW; Alphs L
Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):101-9, 109A. PubMed ID: 23446197
[TBL] [Abstract][Full Text] [Related]
14. Model-Informed Clinical Development of 6-Monthly Injection of Paliperidone Palmitate in Patients with Schizophrenia: Dosing Strategies Guided by Population Pharmacokinetic Modeling and Simulation (Part II).
T'jollyn H; Venkatasubramanian R; Neyens M; Gopal S; Russu A; Nandy P; Perez-Ruixo JJ; Ackaert O
Eur J Drug Metab Pharmacokinet; 2024 Jul; 49(4):491-506. PubMed ID: 38769284
[TBL] [Abstract][Full Text] [Related]
15. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.
Li H; Rui Q; Ning X; Xu H; Gu N
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1002-8. PubMed ID: 21315787
[TBL] [Abstract][Full Text] [Related]
16. Intramuscular paliperidone palmitate.
Hoy SM; Scott LJ; Keating GM
CNS Drugs; 2010 Mar; 24(3):227-44. PubMed ID: 20155997
[TBL] [Abstract][Full Text] [Related]
17. A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia.
Pandina G; Lane R; Gopal S; Gassmann-Mayer C; Hough D; Remmerie B; Simpson G
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jan; 35(1):218-26. PubMed ID: 21092748
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic profile after multiple deltoid or gluteal intramuscular injections of paliperidone palmitate in patients with schizophrenia.
Rossenu S; Cleton A; Hough D; Crauwels H; Vandebosch A; Berwaerts J; Eerdekens M; Herben V; De Meulder M; Remmerie B; Francetic I
Clin Pharmacol Drug Dev; 2015 Jul; 4(4):270-8. PubMed ID: 27136907
[TBL] [Abstract][Full Text] [Related]
19. Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia.
Hough D; Lindenmayer JP; Gopal S; Melkote R; Lim P; Herben V; Yuen E; Eerdekens M
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Aug; 33(6):1022-31. PubMed ID: 19481579
[TBL] [Abstract][Full Text] [Related]
20. A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia.
Pandina GJ; Lindenmayer JP; Lull J; Lim P; Gopal S; Herben V; Kusumakar V; Yuen E; Palumbo J
J Clin Psychopharmacol; 2010 Jun; 30(3):235-44. PubMed ID: 20473057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]